Is Ardent Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Ardent Health, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued, as reflected by its price of 14.63, which is significantly above its 52-week low of 10.10. Key valuation ratios include a price-to-earnings (P/E) ratio that is not specified but suggests a high valuation, alongside the absence of peer comparisons in terms of valuation metrics. In terms of performance, Ardent Health, Inc. has underperformed relative to the S&P 500, with a year-to-date return of -14.34% compared to the index's 13.30%. Over the past year, the stock has declined by 24.97%, while the S&P 500 has gained 14.08%. This stark contrast in returns further supports the conclusion that Ardent Health, Inc. is currently overvalued.